tradingkey.logo

Enanta Pharmaceuticals Q1 revenue beats estimates

ReutersFeb 9, 2026 9:09 PM


Overview

  • Biotechnology firm's fiscal Q1 revenue rose, beating analyst expectations

  • Net loss for fiscal Q1 narrowed compared to the previous year


Outlook

  • Enanta anticipates cash resources to fund operations into fiscal 2029


Result Drivers

  • ROYALTY REVENUE - Revenue increase attributed to higher sales of AbbVie's MAVYRET/MAVIRET, boosting royalty income


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Beat

$18.62 mln

$16.14 mln (4 Analysts)

Q1 EPS

-$0.42

Q1 Net Income

-$11.94 mln

Q1 Operating Expenses

$29.87 mln

Q1 Operating Income

-$11.25 mln

Q1 Pretax Profit

-$11.91 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 48% above its February 6 closing price of $13.51

Press Release: ID:nBw7WR173a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI